In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

J&J to buy remainder of Crucell for €2bn

Executive Summary

To build up a vaccines franchise, Johnson & Johnson has agreed to pay $2.2bn (€2bn) in cash (or $32.29 per share, a 24% premium) for the 82.1% of Crucell NV (developing antibodies and vaccines for infectious diseases) that J&J does not already own.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Partial Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register